Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2022 02:00 ET | Source: Quantum Genomics

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new...
October 06, 2022 12:00 ET | Source: Quantum Genomics

Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products...
October 05, 2022 12:00 ET | Source: Quantum Genomics

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products...
September 26, 2022 10:07 ET | Source: Quantum Genomics

Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension

PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that...
June 27, 2022 12:47 ET | Source: Quantum Genomics

Quantum Genomics announces the appointment of its new Scientific Advisory Board

PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting...
May 09, 2022 12:00 ET | Source: Quantum Genomics

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting...
May 04, 2022 12:00 ET | Source: Quantum Genomics

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting...
April 28, 2022 12:00 ET | Source: Quantum Genomics

Quantum Genomics Publishes its Results for Fiscal Year 2021 and Provides a Corporate Update

PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products...
April 27, 2022 08:20 ET | Source: Quantum Genomics

Quantum Genomics Announces Successful Capital Raise with a Gross Sum of Approximately 15.6M€

Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and explore new therapeutic fields based on the patented technology platform built around...
April 26, 2022 11:35 ET | Source: Quantum Genomics

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription rightA minimum of €12 million subscription commitments received...